LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Inicio・Lista de Acciones・Organon & Co

Search

Organon & Co

Cerrado

SectorSanidad

13.38 -0.22

Resumen

Variación precio

24h

Actual

Mínimo

13.37

Máximo

13.42

Métricas clave
By Trading Economics
Ingresos	351M 146M
Ventas	-47M 1.5B
P/B Media del Sector	14.441 50.102
BPA	0.71
Rentabilidad por dividendo	0.6
Margen de beneficios	10
Empleados	10,000
EBITDA	286M 351M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	-8.05% downside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	0.60% 2.33%
Próximas Ganancias	4 ago 2026
Fecha Próximo Dividendo	11 jun 2026
Próxima Fecha de Ex Dividendo	14 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	71M 3.5B
Apertura anterior	13.6
Cierre anterior	13.38

Noticias sobre sentimiento de mercado

By Acuity

74%

26%

306 / 344 Clasificación en Healthcare

Organon & Co Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 abr 2026, 06:09 UTC

Adquisiciones, fusiones, absorciones

India's Sun Pharma to Buy U.S. Healthcare Company Organon in $11.75 Billion Deal -- 2nd Update

27 abr 2026, 02:33 UTC

Adquisiciones, fusiones, absorciones

India's Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal - Update

27 abr 2026, 01:04 UTC

Adquisiciones, fusiones, absorciones

Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion

7 nov 2025, 14:41 UTC

Adquisiciones, fusiones, absorciones

Laborie to Buy Specialist Medical Device For Up To $465 Million From Organon

27 abr 2026, 18:07 UTC

Adquisiciones, fusiones, absorciones

Organon Rides the Pharma M&A Wave With Sun Takeover. The Stock Sizzles. -- Barrons.com

27 abr 2026, 15:14 UTC

Adquisiciones, fusiones, absorciones

Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal -- Update

27 abr 2026, 14:56 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27 abr 2026, 13:58 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27 abr 2026, 13:38 UTC

Acciones populares

Stocks to Watch Monday: Frontier, Domino's Pizza, Qualcomm -- WSJ

27 abr 2026, 12:18 UTC

Adquisiciones, fusiones, absorciones

Another Pharma Takeover Shows the Sector Is Hot. Organon Stock Rides the M&A Wave. -- Barrons.com

27 abr 2026, 09:22 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Jumps After Sun Seals Takeover. Why Pharma M&A Is a Hot Play. -- Barrons.com

27 abr 2026, 00:38 UTC

Adquisiciones, fusiones, absorciones

Sun Pharmaceutical to Acquire Organon Shares for $14.00 Each in an All Cash Deal

27 abr 2026, 00:38 UTC

Adquisiciones, fusiones, absorciones

Sun Pharmaceutical to Acquire Organon & Co. at an Enterprise Value of $11.75B

24 abr 2026, 20:51 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 20:39 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 19:25 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 17:09 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

10 abr 2026, 20:10 UTC

Adquisiciones, fusiones, absorciones

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 abr 2026, 14:39 UTC

Adquisiciones, fusiones, absorciones

Update: This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 abr 2026, 14:01 UTC

Adquisiciones, fusiones, absorciones

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 abr 2026, 09:23 UTC

Acciones populares

Stocks to Watch Friday: Lumentum, Coherent, Porsche -- WSJ

Comparación entre iguales

Cambio de precio

Organon & Co previsión

Precio Objetivo

By TipRanks

-8.05% descenso

Estimación a 12 Meses

Media 12.33 USD -8.05%

Máximo 14 USD

Mínimo 9 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Organon & Co Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

0

Comprar

4

Mantener

0

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Organon & Co Dist en los últimos 3 meses.

Sentimiento

By Acuity

306 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Otras acciones del sector

LLY

Eli Lilly and Co.

1,085.59

JNJ

Johnson and Johnson

231.35

ABBV

AbbVie Inc

215.42

UNH

UnitedHealth Group Inc

384.08

MRK

Merck & Co Inc.

120.33

Live chat